It’s evidence of another global jurisdiction who sees material benefit in Wheezo as a core part of a platform to manage asthma along with a smart inhaler…nothing fluffy about that at all actually very material in what it means to the process of the company’s technology adoption. Focus is still on the US market as the main priority.
Ann: New GBP2m NIHR-Funded UK Paediatric Asthma Clinical Trial, page-8
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.54M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 800000 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 508500 | 3 |
View Market Depth
| Last trade - 16.12pm 11/09/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable